Developing cutting- edge cell therapies.
BioSyngen was established in Singapore on 1 July 2016 as an immuno-oncology company. It collaborates with leading biomedical research and clinical institutes in Germany, Australia, China and Singapore
Developing cutting-edge immunotherapies to address unmet needs in oncology.
Advancing R&D through our network of international partners.
Achieving better outcomes for cancer patients
WORK WITH US
Take part in our mission to deliver more effective cancer care and improve patient outcomes.
i. Founding Partner, ABC Capital; President, ABC Group.
ii. Chairman of Board
Founder & Chairman, Stone Capital
Entrepreneur & Investor
Deputy Group CEO, National Healthcare Group, Singapore
CEO & CMO